← Back to Clinical Trials
Recruiting NCT07472686

NCT07472686 Small Bowel Capsule Endoscopy in Lynch Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07472686
Status Recruiting
Phase
Sponsor Assistance Publique - Hôpitaux de Paris
Condition MMR Mutation
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2025-06-16
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2025-06-16 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The impact of small bowel (SB) capsule endoscopy (CE) on the screening (followed by diagnosis and treatment) of (pre)neoplastic lesions of the small bowel in Lynch syndrome (LS) patients is unknown. The iCARE4Lynch study is a retrospective cohort of patients carrying a pathogenic variant of the DNA mismatch repair gene (MMR) (MLH1, MSH2, MSH6, PMS2, EPCAM) who had had at least one SBCE for screening of small bowel (pre)neoplastic lesions between January 1st 2000 and December 31 2024.

Eligibility Criteria

Inclusion Criteria: * Patient carrying a pathogenic variant of the DNA mismatch repair gene (MMR) (MLH1, MSH2, MSH6, PMS2, EPCAM) * Capsule endoscopy screening for (pre)neoplastic lesions of the small intestine * No opposition to the reuse of healthcare data for research purposes Exclusion Criteria: * Absence of documented MMR gene variant * Opposition to the study

Contact & Investigator

Central Contact

Xavier DRAY, MD PhD

✉ xavier.dray@aphp.fr

📞 +33 (0) 1 49 28 21 61

Frequently Asked Questions

Who can join the NCT07472686 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying MMR Mutation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07472686 currently recruiting?

Yes, NCT07472686 is actively recruiting participants. Contact the research team at xavier.dray@aphp.fr for enrollment information.

Where is the NCT07472686 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT07472686 clinical trial?

NCT07472686 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology